MA40894A - Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production - Google Patents

Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Info

Publication number: MA40894A
Authority: MA; Morocco
Prior art keywords: lymphocytes; target; production processes; heterodimeric immunoglobulins; heterodimeric
Prior art date: 2014-11-04

Application number

MA040894A

Other languages

English (en)

Inventor

Jonathan Back

Samuel Hou

Rami Lissilaa

Romain Ollier

Darko Skegro

Original Assignee

Glenmark Pharmaceuticals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-11-04

Filing date

2015-11-02

Publication date

2017-09-12

2014-11-04 Priority claimed from PCT/EP2014/073738 external-priority patent/WO2015063339A1/fr

2015-11-02 Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa

2017-09-12 Publication of MA40894A publication Critical patent/MA40894A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Hematology (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

MA040894A 2014-11-04 2015-11-02 Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production MA40894A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
PCT/EP2014/073738 WO2015063339A1 (fr)	2013-11-04	2014-11-04	Production de cellules t reciblant des immunoglobulines héréro-dimériques
EP15167034		2015-05-08

Publications (1)

Publication Number	Publication Date
MA40894A true MA40894A (fr)	2017-09-12

Family

ID=53059011

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA040894A MA40894A (fr)	2014-11-04	2015-11-02	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production

Country Status (20)

Country	Link
EP (1)	EP3215541A1 (fr)
JP (3)	JP2018501297A (fr)
KR (1)	KR102760422B1 (fr)
CN (1)	CN107207596A (fr)
AU (1)	AU2015341884B2 (fr)
BR (1)	BR112017009263A2 (fr)
CA (1)	CA2965745C (fr)
CL (1)	CL2017001090A1 (fr)
CO (1)	CO2017005240A2 (fr)
EA (1)	EA039658B1 (fr)
HK (1)	HK1244014A1 (fr)
IL (1)	IL251848A0 (fr)
MA (1)	MA40894A (fr)
MX (1)	MX2017005814A (fr)
MY (1)	MY186929A (fr)
NZ (1)	NZ732019A (fr)
PE (1)	PE20171041A1 (fr)
PH (1)	PH12017500819A1 (fr)
SG (1)	SG11201703313SA (fr)
WO (1)	WO2016071355A1 (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12466897B2 (en)	2011-10-10	2025-11-11	Xencor, Inc.	Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2014205086B2 (en)	2013-01-14	2019-04-18	Xencor, Inc.	Novel heterodimeric proteins
US11053316B2 (en)	2013-01-14	2021-07-06	Xencor, Inc.	Optimized antibody variable regions
US10858417B2 (en)	2013-03-15	2020-12-08	Xencor, Inc.	Heterodimeric proteins
DK3024851T3 (en)	2013-07-25	2018-08-06	Cytomx Therapeutics Inc	MULTI-SPECIFIC ANTIBODIES, MULTI-SPECIFICALLY ACTIVABLE ANTIBODIES, AND METHODS FOR USING IT
MY176522A (en)	2013-11-04	2020-08-13	Ichnos Sciences SA	Production of t cell retargeting hetero-dimeric immunoglobulins
JP6775422B2 (ja)	2014-03-28	2020-10-28	ゼンコー・インコーポレイテッドＸｅｎｃｏｒ、Ｉｎｃ．	Ｃｄ３８及びｃｄ３に結合する二重特異性抗体
US10669337B2 (en) *	2014-07-25	2020-06-02	Cytomx Therapeutics, Inc.	Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
US11773166B2 (en)	2014-11-04	2023-10-03	Ichnos Sciences SA	CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US10526417B2 (en)	2014-11-26	2020-01-07	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and CD38
AU2015353409B2 (en)	2014-11-26	2019-05-09	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
US10259887B2 (en)	2014-11-26	2019-04-16	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and tumor antigens
TWI829617B (zh)	2015-07-31	2024-01-21	德商安美基研究（慕尼黑）公司	Ｆｌｔ３及ｃｄ３抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
TWI796283B (zh)	2015-07-31	2023-03-21	德商安美基研究（慕尼黑）公司	Ｍｓｌｎ及ｃｄ３抗體構築體
US10227410B2 (en)	2015-12-07	2019-03-12	Xencor, Inc.	Heterodimeric antibodies that bind CD3 and PSMA
CA3011942A1 (fr)	2016-02-03	2017-08-10	Amgen Research (Munich) Gmbh	Constructions d'anticorps impliquant des cellules t bispecifiques psma et cd3
CN110352070B (zh)	2016-06-14	2024-09-17	Xencor股份有限公司	双特异性检查点抑制剂抗体
EP4050032A1 (fr)	2016-06-28	2022-08-31	Xencor, Inc.	Anticorps hétérodimériques qui se lient au récepteur 2 de la somatostatine
JP2020517659A (ja) *	2017-04-24	2020-06-18	イクノスサイエンシズエスエー	Ｅｇｆｒ陽性癌の治療のためのｔ細胞リダイレクト二重特異性抗体
CA3064163A1 (fr) *	2017-06-05	2018-12-13	Numab Therapeutics AG	Nouveaux anticorps anti-cd3
WO2018224441A1 (fr) *	2017-06-05	2018-12-13	Numab Innovation Ag	Nouveaux anticorps anti-cd3
CA3066555A1 (fr) *	2017-06-08	2018-12-13	Black Belt Therapeutics Limited	Anticorps permettant de moduler cd38
AU2018280868B2 (en)	2017-06-08	2024-09-26	Black Belt Therapeutics Limited	CD38 modulating antibody
AR112357A1 (es) *	2017-08-10	2019-10-23	Grifols Diagnostic Solutions Inc	Composiciones, procedimientos y/o kits que comprenden un dominio extracelular recombinante de cd38 humano
WO2019035938A1 (fr)	2017-08-16	2019-02-21	Elstar Therapeutics, Inc.	Molécules multispécifiques se liant à bcma et leurs utilisations
US11542338B2 (en)	2017-08-16	2023-01-03	Black Belt Therapeutics Limited	CD38 modulating antibody
KR102770110B1 (ko)	2017-08-16	2025-02-20	블랙 벨트 테라퓨틱스 리미티드	Cd38 항체
KR102770107B1 (ko)	2017-08-16	2025-02-20	블랙 벨트 테라퓨틱스 리미티드	Cd38 조정 항체
SG11202002384VA (en)	2017-10-14	2020-04-29	Cytomx Therapeutics Inc	Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP3706793A1 (fr)	2017-11-08	2020-09-16	Xencor, Inc.	Anticorps bispécifiques et monospécifiques utilisant de nouvelles séquences anti-pd-1
US10982006B2 (en)	2018-04-04	2021-04-20	Xencor, Inc.	Heterodimeric antibodies that bind fibroblast activation protein
MX2021003407A (es) *	2018-09-25	2021-09-23	Ichnos Sciences S A	Cuantificacion de anticuerpos en muestras biologicas.
KR102353568B1 (ko) *	2018-11-14	2022-01-20	주식회사 헬릭스미스	안정성이 향상된 항 c-Met 항체 또는 그의 항원 결합 단편
KR20210119448A (ko) *	2019-01-23	2021-10-05	앙세파	Cd31 경쟁인자(competitor) 및 이의 용도
US20220177582A1 (en) *	2019-03-13	2022-06-09	Ichnos Sciences SA	Non-consensus glycosylation of bispecific antibodies
CA3139111A1 (fr) *	2019-05-23	2020-11-26	VelosBio Inc.	Molecules de liaison bispecifiques anti-ror1/anti-cd3
WO2020250940A1 (fr) *	2019-06-11	2020-12-17	小野薬品工業株式会社	Agent d'immunosuppression
CN110551222B (zh) *	2019-08-27	2023-06-06	重庆市畜牧科学院	一种新型双功能抗体及其用途
CN112538114B (zh) *	2019-09-20	2025-05-02	上海普铭生物科技有限公司	抗人cd38抗体及其应用
EP4039707A4 (fr) *	2019-09-30	2022-11-16	Harbour Biomed (Shanghai) Co., Ltd	Anticorps de ciblage de cd3, anticorps bispécifique et son utilisation
CN113493519B (zh) *	2020-03-19	2022-12-27	浙江道尔生物科技有限公司	一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白
WO2021185002A1 (fr)	2020-03-19	2021-09-23	深圳纽迪瑞科技开发有限公司	Procédé de préparation d'un film sensible à la contrainte, film sensible à la contrainte et capteur de pression
US20230212289A1 (en) *	2020-04-24	2023-07-06	Memorial Sloan Kettering Cancer Center	Anti-cd3 antibodies and uses thereof
WO2021231976A1 (fr)	2020-05-14	2021-11-18	Xencor, Inc.	Anticorps hétérodimères qui se lient à l'antigène membranaire spécifique de la prostate (psma) et cd3
JP2023530675A (ja) *	2020-06-17	2023-07-19	ワイ－マブスセラピューティクス，インコーポレイテッド	ヒト疾患の治療のためのｃｄ３８抗体
IL300666A (en)	2020-08-19	2023-04-01	Xencor Inc	ANTI–CD28 COMPOSITIONS
JP2024511319A (ja)	2021-03-09	2024-03-13	ゼンコアインコーポレイテッド	Ｃｄ３及びｃｌｄｎ６に結合するヘテロ二量体抗体
JP2024509274A (ja)	2021-03-10	2024-02-29	ゼンコアインコーポレイテッド	Ｃｄ３及びｇｐｃ３に結合するヘテロ二量体抗体
CN118043357A (zh) *	2021-08-04	2024-05-14	阿布普罗公司	Cd3靶向抗体及其用途
CN118108852B (zh) *	2023-11-23	2025-11-18	浙江大学	一种抗啶虫脒单克隆抗体及其重组全长IgG表达质粒

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2511297E (pt) *	2004-02-06	2015-08-24	Morphosys Ag	Anticorpos humanos anti-cd38 e utilizações dos mesmos
IL296666A (en) *	2005-03-23	2022-11-01	Genmab As	Antibodies against 38cd for the treatment of multiple myeloma
SI2860192T1 (en) *	2005-10-12	2018-04-30	Morphosys Ag	Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38
EP1914242A1 (fr) *	2006-10-19	2008-04-23	Sanofi-Aventis	Nouveau anticorps Anti-CD38 pour le traitement du cancer
EP2975051B1 (fr) *	2009-06-26	2021-04-14	Regeneron Pharmaceuticals, Inc.	Anticorps bispécifiques facilement isolés avec un format natif d'immunoglobuline
BR112012017124C1 (pt) *	2009-12-25	2021-08-31	Chugai Pharmaceutical Co Ltd	Método para produzir e para purificar um multímero polipeptídico
PL2580243T3 (pl) *	2010-06-09	2020-05-18	Genmab A/S	Przeciwciała przeciwko ludzkiemu CD38
JOP20210044A1 (ar) *	2010-12-30	2017-06-16	Takeda Pharmaceuticals Co	الأجسام المضادة لـ cd38
MX358752B (es) *	2011-03-25	2018-08-31	Glenmark Pharmaceuticals Sa	Inmunoglobulinas heterodiméricas.
US20150239991A1 (en) *	2012-09-25	2015-08-27	Glenmark Pharmaceuticals S.A.	Purification of hetero-dimeric immunoglobulins
EP2914302B1 (fr) *	2012-11-05	2017-01-04	MorphoSys AG	Anticorps radiomarqué et ses utilisations
MY176522A (en) *	2013-11-04	2020-08-13	Ichnos Sciences SA	Production of t cell retargeting hetero-dimeric immunoglobulins

2015
- 2015-11-02 MA MA040894A patent/MA40894A/fr unknown
- 2015-11-03 WO PCT/EP2015/075628 patent/WO2016071355A1/fr not_active Ceased
- 2015-11-03 PE PE2017000802A patent/PE20171041A1/es unknown
- 2015-11-03 HK HK18103440.0A patent/HK1244014A1/zh unknown
- 2015-11-03 MX MX2017005814A patent/MX2017005814A/es unknown
- 2015-11-03 CN CN201580072196.8A patent/CN107207596A/zh active Pending
- 2015-11-03 EP EP15790129.9A patent/EP3215541A1/fr not_active Withdrawn
- 2015-11-03 JP JP2017542319A patent/JP2018501297A/ja active Pending
- 2015-11-03 MY MYPI2017701499A patent/MY186929A/en unknown
- 2015-11-03 SG SG11201703313SA patent/SG11201703313SA/en unknown
- 2015-11-03 AU AU2015341884A patent/AU2015341884B2/en active Active
- 2015-11-03 KR KR1020177015252A patent/KR102760422B1/ko active Active
- 2015-11-03 BR BR112017009263-8A patent/BR112017009263A2/pt not_active Application Discontinuation
- 2015-11-03 NZ NZ732019A patent/NZ732019A/en unknown
- 2015-11-03 EA EA201790961A patent/EA039658B1/ru unknown
- 2015-11-03 CA CA2965745A patent/CA2965745C/fr active Active
2017
- 2017-04-23 IL IL251848A patent/IL251848A0/en unknown
- 2017-05-02 CL CL2017001090A patent/CL2017001090A1/es unknown
- 2017-05-03 PH PH12017500819A patent/PH12017500819A1/en unknown
- 2017-05-26 CO CONC2017/0005240A patent/CO2017005240A2/es unknown
2019
- 2019-07-23 JP JP2019135318A patent/JP2019214582A/ja active Pending
2021
- 2021-08-02 JP JP2021126392A patent/JP7403505B2/ja active Active

Also Published As

Publication number	Publication date
EA039658B1 (ru)	2022-02-22
AU2015341884B2 (en)	2020-09-17
IL251848A0 (en)	2017-06-29
KR102760422B1 (ko)	2025-02-03
CA2965745C (fr)	2023-12-05
JP2018501297A (ja)	2018-01-18
BR112017009263A2 (pt)	2018-01-30
CA2965745A1 (fr)	2016-05-12
JP2019214582A (ja)	2019-12-19
JP2021184722A (ja)	2021-12-09
AU2015341884A1 (en)	2017-06-08
WO2016071355A1 (fr)	2016-05-12
PH12017500819A1 (en)	2017-10-02
KR20170078831A (ko)	2017-07-07
CN107207596A (zh)	2017-09-26
CO2017005240A2 (es)	2017-10-31
JP7403505B2 (ja)	2023-12-22
SG11201703313SA (en)	2017-05-30
EA201790961A1 (ru)	2017-10-31
PE20171041A1 (es)	2017-07-19
CL2017001090A1 (es)	2018-01-05
HK1244014A1 (zh)	2018-07-27
EP3215541A1 (fr)	2017-09-13
NZ732019A (en)	2022-07-29
MX2017005814A (es)	2017-08-02
MY186929A (en)	2021-08-26

Publication	Publication Date	Title
MA40894A (fr)	2017-09-12	Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production
HUS2500002I1 (hu)	2025-01-28	Újszerû anti-PD-L1 antitestek
EP3706784A4 (fr)	2021-12-01	Compositions et procédés de production de lymphocytes t
IL252467A0 (en)	2017-07-31	Heterodimeric antibodies that bind cd3 and cd38
IL255727A (en)	2018-01-31	Novel anti-pd-l1 antibodies
IL248007A0 (en)	2016-11-30	Bispecific antibodies that bind to cd38 and cd3
MA40889A (fr)	2017-09-12	Immunoglobulines héréro-dimériques reciblant des lymphocytes
EP3397263A4 (fr)	2019-06-26	Procédés de production de lymphocytes t et lymphocytes t ainsi produits
SG10201603721TA (en)	2017-12-28	Anti-CTLA-4 Antibodies
EP2991646A4 (fr)	2016-11-02	Procédés et compositions pour augmenter les lymphocytes t cd4+ régulateurs
EP3341485A4 (fr)	2019-03-27	Production améliorée d'immunoglobulines
MA41375A (fr)	2017-11-28	Anticorps igg bispécifiques et leurs procédés de préparation
EP3515503A4 (fr)	2020-09-23	Lymphocytes modifiés
MA42829A (fr)	2021-04-14	Compositions dérivées de placenta et procédés pour les produire
MA39915A (fr)	2017-03-22	Composés de pladiénolide pyridine et leurs procédés d'utilisation
EP3368087A4 (fr)	2019-06-19	Produit de scellement bioadhésif composite
FI20155385A7 (fi)	2016-11-26	Menetelmät tuotteiden jatkuvaksi tuottamiseksi mikro-organismeista
HUE059655T2 (hu)	2022-12-28	Új anti-humán GPVI antitestek és felhasználásuk
MA44517A (fr)	2019-02-06	Compositions d'immunoglobuline intraveineuse recombinante (rivig) et leurs procédés de production et d'utilisation
EP3154360C0 (fr)	2023-09-20	Produits laitiers et leurs procédés de production
EP3393269A4 (fr)	2019-07-17	Compositions de protéines végétales fermentées procédés pour les produire
EP3340979A4 (fr)	2019-07-17	Compositions et procédés pour la sensibilisation de parasites à un médicament
EP3324983A4 (fr)	2019-04-10	Procédés et matières pour produire des lymphocytes t
EP3365015A4 (fr)	2019-07-24	Compositions et procédés pour thérapie anticancéreuse à médiation immunitaire
EP3344661C0 (fr)	2023-06-07	Complexes de fer-polysaccharide et leurs procédés de préparation